Drug Discovery workshop
MAASCC propose a workshop to get basics about Drug Discovery.At the end of this workshop you should: have a better understanding of the global Drug Discovery process in a Pharma Industry Context be more familiar with the concepts of Target Product Profile (TPP), Target Candidate Profile (TCP), tests cascadebe able to make a difference between a hit, a lead and a development candidatehave an idea of what is ADME and how it is used to select or optimize compoundsYou should be convinced modern drug discovery is multidisciplinary and multiparametric with quality at the heart of the process and be prepared to work in complex collaborative projects.Date: May 28 - 18:00 - 20:00 (1 hour conference & questions)Public concerned: Pasteurians (PhD students, Post-docs, Researchers, Research assistants) & Alumni(limited to 20 people)RegisterAbout the trainer:Dr. Gilles CourtemancheAntimicrobials Program HeadBioaster Technology Research InstituteParis, FranceGilles Courtemanche got his PhD on Synthetic Chemistry (1991) at Pierre & Marie Curie University Paris, France. He has been working in the pharma industry for more than 20 years. First he took a position of Scientist and worked in Central Nervous System field where he participated in the discovery of the first CRF antagonists (1991-1994). Next, as a project leader at Synthelabo, he contributed in the nomination of several drug candidates for development phase in Urology, Gastroenterology and Metabolism fields. Then, he took of position of Group Leader in Medicinal Chemistry, where he managed a team of up to 30 medicinal chemists working in the field of Infectious Diseases. Finally, he took the responsibility of Collaborative Research on Neglected Tropical Diseases at Sanofi where he worked in collaboration with not for profit organizations like DNDi or MMV, and several international academic partners. He has filed more than 20 patent applications. Currently, he is working for Bioaster, a Technology Research Institute for Health, where he is heading the Antimicrobials Unit. His mission is to build public-private collaborative projects to overcome technical bottlenecks that impair the discovery or development or drugs against Infectious Diseases.